O-glcnacylation contributes to augmented vascular reactivity induced by endothelin 1

Hypertension

Volumn 55, Issue 1, 2010, Pages 180-188

  Lima, Victor V ^a   Giachini, Fernanda R ^a   Carneiro, Fernando S ^a,b   Carneiro, Zidonia N ^a   Saleh, Mohamed A ^a   Pollock, David M ^a   Fortes, Zuleica B ^b   Carvalho, Maria Helena C ^b   Ergul, Adviye ^a   Webb, R Clinton ^a   Tostes, Rita C ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

N acetylglucosamine (O GlcNAc); N acetylglucosaminidase; Endothelin 1; Hypertension; Vascular reactivity

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENZYME ANTIBODY; GLYCOSIDASE INHIBITOR; N ACETYL BETA GLUCOSAMINIDASE; N ACETYLGLUCOSAMINE; O ACETYLGLUCOSAMINE TRANSFERASE; PHENYLEPHRINE; TRANSFERASE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; CONFERENCE PAPER; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; SYSTOLIC BLOOD PRESSURE; TIME;

ACETYLGLUCOSAMINE; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; BLOTTING, WESTERN; DESOXYCORTICOSTERONE; DRUG SYNERGISM; ENDOTHELIN-1; GLYCOPROTEINS; GLYCOSYLATION; HYPERTENSION; MALE; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHENYLEPHRINE; PYRROLIDINES; RATS; RATS, WISTAR; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 73849145046     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.143818     Document Type: Conference Paper

References (26)

1. Hart GW, Housley MP, Slawson C. Cycling of O-linked /3-N- acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446: 1017-1022.
2. Fülop N, Marchase RB, Chatham JC. Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc Res. 2007;73:288297.
3. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol. 2009;296:H13-H28.
4. Musicki B, Kramer MF, Becker RE, Burnett AL. N-activation of phos-phorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA. 2005; 102:11870-11875.
5. Whitworth CE, Macauley MS, Stubbs KA, Dennis RJ, Taylor EJ, Vocadlo DJ. Analysis of PugNag and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J Am Chem Soc. 2007;129:635-644.
6. Lima VV, Giachini FR, Carneiro FS, Carneiro ZN, Fortes ZB, Carvalho MHC, Webb RC, Tostes RC. Increased vascular O-GlcNAcylation augments reactivity to constrictor stimuli. JASH. 2008;2:410-417.
7. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation. 2002;106:466-472.
8. Lima VV, Giachini FR, Choi H, Carneiro FS, Carneiro ZN, Fortes ZB, Carvalho MH, Webb RC, Tostes RC. Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation. Hypertension. 2009;53:166-174.
9. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005;43:19-29.
10. Tostes RC, Muscara MN. Endothelin receptor antagonists: another potential alternative for cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:287-301.
11. Carneiro FS, Nunes KP, Giachini FR, Lima VV, Carneiro ZN, Nogueira EF, Leite R, Ergul A, Rainey WE, Clinton Webb R, Tostes RC. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension. J Sex Med. 2008;5: 2793-2807.
12. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19:1173-1176.
13. Keller M, Lidington D, Vogel L, Peter BF, Sohn HY, Pagano PJ, Pitson S, Spiegel S, Pohl U, Bolz SS. Sphingosine kinase functionally links elevated transmural pressure and increased reactive oxygen species formation in resistance arteries. FASEB J. 2006;20:702-704.
14. Clarke CJ, Forman S, Pritchett J, Ohanian V, Ohanian J. Phospholipase C-delta1 modulates sustained contraction of rat mesenteric small arteries in response to noradrenaline, but not endothelin-1. Am J Physiol Heart Circ Physiol. 2008;295:H826-H834.
15. Chitaley K, Webb RC, Dorrance AM, Mills TM. Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats. Int J Impot Res. 2001;13(suppl 5):S16-S20.
16. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237: E214-E223.
17. Giachini FRC, Carneiro FS, Lima VV, Carneiro ZN, Carvalho MHC, Fortes ZB, Webb RC, Tostes RC. Pyk2 mediates increased adrenergic contractile responses in arteries from DOCA-salt mice. J Am Soc Hypertens. 2008;2:431-438.
18. Dong DL, Hart GW. Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. J Biol Chem. 1994;269:19321-19330.
19. Dehennaut V, Lefebvre T, Sellier C, Leroy Y, Gross B, Walker S, Cacan R, Michalski JC, Vilain JP, Bodart JF. O-linked N-acetylglucosaminyltransferase inhibition prevents G2/M transition in Xenopus laevis oocytes. J Biol Chem. 2007;282:12527-12536.
20. Zachara NE, Hart GW. Cell signaling, the essential role of O-GlcNAc! Biochim Biophys Acta. 2006;1761:599-617.
21. Comer FI, Hart GW. Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry. 2001;40:7845-7852.
22. Xing D, Feng W, Not LG, Miller AP, Zhang Y, Chen YF, Majid-Hassan E, Chatham JC, Oparil S. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol. 2008;295:H335-H342.
23. Giachini FR, Callera GE, Carneiro FS, Tostes RC, Webb RC. Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? Expert Opin Ther Targets. 2008;12:327-339.
24. Wang Y, Wang DH. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol. 2004;287:H1868-H1874.
25. Bohr DF, Dominiczak AF, Webb RC. Pathophysiology of the vasculature in hypertension. Hypertension. 1991;18:III69-III75.
26. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW. O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J Biol Chem. 2008;283:33935-33941.